NCT06072781 2026-03-17
RAMP 301
Verastem, Inc.
Phase 3 Recruiting
Clinical Trials
30 trialsNCT06016738 2026-03-13
OPERA-01
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT07174336 2026-03-06
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT02763566 2026-02-05
MONARCH plus
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02246621 2026-02-03
MONARCH 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05514054 2026-01-29
EMBER-4
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05645536 2026-01-12
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
Phase 3 Enrolling by invitation
NCT04711252 2025-10-14
SERENA-4
AstraZeneca
Phase 3 Active not recruiting
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT05257395 2025-07-17
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT05952557 2025-06-19
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT02278120 2024-03-12
MONALEESA-7
Novartis
Phase 3 Completed
NCT05780567 2023-04-21
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT03966898 2021-06-02
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT00295620 2019-10-02
SALSA
AstraZeneca
Phase 3 Completed
NCT00248170 2016-04-19
FACE
Novartis
Phase 3 Completed
NCT00022672 2013-06-13
A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00605267 2012-09-06
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
AstraZeneca
Phase 3 Completed
NCT00256698 2012-08-01
FACT
AstraZeneca
Phase 3 Completed
NCT00143390 2012-01-25
Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer
Pfizer
Phase 3 Completed
NCT00327769 2011-01-25
Faslodex Advanced Breast Cancer Local Chinese Study
AstraZeneca
Phase 3 Completed
NCT00232661 2010-02-03
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
AstraZeneca
Phase 3 Completed
NCT00784862 2009-05-15
ATAC - Pharmacokinetics (PK) Sub-Protocol
AstraZeneca
Phase 3 Completed
NCT00286117 2009-05-01
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
AstraZeneca
Phase 3 Completed
NCT00300508 2009-05-01
3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer
AstraZeneca
Phase 3 Completed
NCT00784680 2009-05-01
ATAC - Quality of Life Sub-Protocol
AstraZeneca
Phase 3 Completed
NCT00814125 2009-05-01
ATAC - Endometrial Sub-Protocol
AstraZeneca
Phase 3 Completed
NCT00784940 2009-04-27
ATAC - Bone Density Sub-Protocol
AstraZeneca
Phase 3 Completed
NCT00635713 2009-04-10
Second Line Breast Cancer Trial
AstraZeneca
Phase 3 Completed